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Abstract
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Liver receptor homolog 1 (LRH1), directs the development and differentiation of embryonic
pancreas, and is overexpressed in pancreatic cancer (PC). We hypothesized that LRH1 promotes
PC growth. Cell proliferation and tumorigenicity in nude mice were compared between empty
vector-transfected (control) and stable LRH1-overexpressed PC cell lines. The subsequent tumor
burden, vasculature development, and histologic features were evaluated. LRH1 overexpression
enhanced the expression of downstream target genes (cyclin D1/E1) and stimulated cell
proliferation in PC cell lines. LRH1 upregulated cyclin E1 truncated T1/T2 isoforms expression
which may occur through ERα—calpain1 signaling. Compared with the control, LRH1
overexpressing stable cells generated tumors with increased weight, proliferation index and
enhanced angiogenesis. Cyclin D1/E1 and calpain1 were overexpressed in human PC tumors
compared to adjacent normal pancreas. These observations demonstrate that LRH1 promotes PC
growth and angiogenesis, suggesting that LRH1 is a driving factor in tumorigenesis and may serve
as a potential therapeutic target.
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1. INTRODUCTION
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Pancreatic cancer (PC) is the fourth-leading cause of cancer mortality in the United States,
with an estimated 43,920 new cases and 37,390 deaths in 2012.[12] PC has the lowest 5year survival rate of all malignancies due to aggressive progression and multiple-drug
resistance.[12] Previous studies have revealed that signaling pathways involved in the
development of the embryonic pancreas also play major roles in the malignant
transformation of the adult pancreas.[9, 13] We hypothesize that liver receptor homolog 1
(LRH1) (also called Nuclear Receptor Subfamily 5 Group A Member 2 [NR5A2]) is a
driving factor that is shared between pancreatic embryogenesis and oncogenesis.[7] LRH1 is
a promoter binding factor and an alpha-fetoprotein transcriptional factor. LRH1 is a key
downstream target of the pancreatic and duodenal homeobox 1 regulatory cascade that
regulates pancreatic development, differentiation, and function.[1]
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Importantly, accumulating evidence indicates participation of LRH1 in the pathogenesis of
multiple tumors, such as gastric, [15] breast, [14] colon, [11] and PC.[4, 10] For example,
LRH1 affects tumor response to anti-estrogen drugs by regulating the expression of estrogen
receptor in breast cancer cells.[14] In the intestine, LRH1 and β-catenin/Tcf4 signaling
induces G1/S-specific cyclin D1/E1-mediated cell proliferation and self-renewal.[5] LRH1
contributes to intestinal tumor formation by affecting both cell cycle control and the
inflammatory process.[11] Notably, a recent genome-wide association study identified
single nucleotide polymorphisms of the LRH1 gene associated with PC risk.[10] LRH1
mRNA level was higher in PC cell lines compared to a normal pancreatic ductal epithelium
derived cell line, and is associated with increased protein levels in pancreatic tumors.[4]
LRH1 expression upregulated mRNA levels of cyclin D1/E1 in PC cell lines.[4]
Accordingly, selective blocking of LRH1 by siRNA decreased mRNA levels of cyclin D1/
E1.[4] However, the mechanism by which LRH1 promotes PC development remains
unclear. To explore the oncogenic property of LRH1, we investigated how LRH1
contributes to PC growth using cell-based assays, xenografts in nude mice, and tissue
specimens of PC.

2. MATIERIALS AND METHODS
2.1 Cell culture
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The human PC cell lines AsPC-1, BxPC-3, Capan-1, HPAF-II, Hs 766T, MIA PaCa-2, PL45
and Panc-1, liver hepatocellular carcinoma cell line HepG2 (ATCC), and non-neoplastic
human pancreatic duct epithelial cell line HPDE (Applied Biological Materials Inc.) were
employed. All the cell lines have been authenticated by short tandem repeat (STR) profiling
to reduce the frequency of cell misidentification.[8] Cells were cultured at 37 °C in a
humidified atmosphere containing 5% CO2 in corresponding medium supplemented with
10% FBS and antibiotics (penicillin and streptomycin). Cells were passaged when they
reached 80% confluence.
2.2 Lentiviral infected stable PC cell lines with overexpression of LRH1
We established two stable Capan-1 and AsPC-1 cell lines with constitutive expression of
LRH1 using the lentiviral expression system (GeneCopoeia, #EX-Z2607-Lv105). After 48 h
of transfection with packaging plasmids and pLentiviral plasmids of target genes in 293T
cells, the supernatants containing lentiviral particles were filtered by 0.45 μm nitrocellulose
membrane and mixed with polybrene at 8 μg/ml. Twenty-four hours after lentiviral
infection, cells were incubated with the corresponding media for 24 h, then selected with 8
μg/mL (for Capan-1) or 3 μg/mL (for AsPC-1) puromycin overtime to eliminate un-infected
cells. The LRH1 protein level in stable PC cell lines was confirmed by Western blot. The

Cancer Lett. Author manuscript; available in PMC 2015 April 01.

Lin et al.

Page 3

selected cell lines were routinely cultured in corresponding puromycin media until two days
before the experiments, the cells were cultured in media without puromycin.
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2.3 Western Blot Analysis
Cell lysates were treated with ConA-sepharose beads overnight followed by centrifugation
to remove cadherin-bound β-catenin. Total Cell lysates and non-membrane bound cell
lysates were separated by SDS PAGE and transferred to nitrocellulose membranes. Western
blot analysis was performed using primary antibodies against LRH1 (Abcam, ab18293),
cyclin D1 (Santa Cruz, sc-8396), cyclin E1 (Santa Cruz, sc-247), calpain1 (Santa Cruz,
sc-7531), β-catenin (Cell signaling Technology, #9562), estrogen receptor alpha (ERα)
(Santa Cruz, sc-7207). Protein bands were visualized by IRDye® 680RD Infrared Dye and
IRDye® 800CW Infrared Dye and exposed on Odyssey image system (LI-COR).
2.4 MTT Assay
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PC cells (vectors vs. LRH1 overexpressing Capan-1 and AsPC-1) (1.7×104 cells per well)
were seeded in 24 well plates and cultured for 4 days. Cells were incubated with MTT
solution (Sigma-Aldrich) in medium (10% v/v) at 37 °C for 3 h. Then 0.1 N HCl
isopropanol was added. Plates were analyzed daily using a plate reader at a wavelength of
570 and 690 nm, respectively. The background absorbance of multiwell plates measured at
690 nm was subtracted from the measurement at 570 nm.
2.5 Subcutaneous tumor model[17]
Athymic BALB/c female nude mice (Charles River laboratory) were housed in laminar flow
cabinets under specific pathogen-free conditions and used at 6–8 weeks of age. All animal
protocols were approved by the Institutional Animal Care and Use Committee of Rhode
Island Hospital. Vectors and LRH1 stable Capan-1 cells in exponential growth phase were
harvested, washed, and resuspended in Ca2+/Mg2+-free HBSS to the desired cell
concentration. Cell viability was determined by trypan blue exclusion and single-cell
suspensions of >90% viability was used. In the subcutaneous (s.c.) model, tumor cells
(5×106 in 0.2 mL of HBSS) were injected subcutaneously into the left (vector) and right
(LRH1) shoulder of the nude mice (n = 7), respectively. The mice were sacrificed after 2
weeks. The tumors were harvested, weighed and fixed with 10% neutral buffered formalin.
To detect nuclear pleomorphism, the section was stained with H&E. IHC for cell
proliferation marker Ki67 and vascular proliferation marker CD34 (Cell Signaling
Technology, #9449 and #3569, respectively) was performed on 4-μm sections of s.c. tumors.
The Ki67 Index (percentage of Ki67-positive pancreatic cancer cell nuclei) was determined
by counting positive and negative staining nuclei.
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2.6 Immunohistochemistry (IHC)
Tissue specimens from 18 patients with stage I/II pancreatic ductal adenocarcinoma were
studied. The study was approved by the Institutional Review Board of Lifespan Rhode
Island and The Miriam Hospital. Immunohistochemical staining was conducted on 4-μm
formalin-fixed paraffin-embedded (FFPE) unstained sections using antibodies to LRH1
(Abcam, ab18293), cyclin D1 (Cell Signaling Technologym #2978), cyclin E1 (Abcam,
ab135380), and calpain1 (Abcam, ab39171). The sections were deparaffinized in xylene and
rehydrated in a descending ethanol gradient. Antigen retrieval was performed using Citric
Acid Based Antigen Unmasking Solution (Vector Laboratories, Burlingame, CA) in a
microwave pressure cooker (Nordic Ware, Minneapolis, MN) for 6 minutes at full power,
followed by a 30 minutes cool down process. Endogenous peroxidase activity was quenched
by a 30-min treatment with 3% hydrogen peroxide in methanol. The remaining steps of the
staining procedure, including blocking, secondary antibody incubation, and ABC reagent
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incubation, were performed using the VECTASTAIN Elite ABC Kit (Vector Laboratories,
Burlingame, CA) according to the manufacturer’s protocol. Primary antibodies were diluted
in TBS/0.1% Tween-20 with 5% normal goat serum and were incubated at 4°C overnight.
Color development was done using DAB Tablet (Wako Chemicals, Richmond, VA) as a
substrate per manufacturer’s instruction. Finally, the sections were counterstained by
hematoxylin, dehydrated in an ascending ethanol gradient, and mounted with
VECTASHIELD Mounting Medium (Vector Laboratories, Burlingame, CA).
2.7 Statistical analysis
All obtained data were calculated and expressed as mean ± SD. Statistical analyses were
performed with the two-tailed Student’s or paired t-test using SPSS software. A p<0.05 was
considered statistically significant.

3. RESULTS
3.1 Expression of LRH1 in PC cells cultured in vitro
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Western blot detected a band of approximately 57 kDa (predicted molecular weight of
LRH1 is 61 kDa). LRH1 was highly expressed in MIA PaCa-2 and to a lesser degree in
Hs766T PC cells, compared with HPDE cells (negative control), as well as HepG2 and
HEK-293 cells transfected with pcDNA3-LRH1 (positive controls) (Fig. 1A). LRH1 protein
was undetectable/very weak in AsPC-1, BxPC-3, Capan-1, HPAF-II, PL45 and Panc-1 cells.
Because of the apparent absence of the LRH1 receptor in these cells, we used AsPC-1 and
Capan-1 to establish stable cell lines for further experiments.
3.2 LRH1 upregulates downstream target genes cyclin D1/E1, ERα and Calpain1
We examined the potential mechanisms of LRH1 involvement in PC by measuring its
downstream target genes. Western blot analysis revealed that cyclin D1 and cyclin E1 (fulllength [FL] and truncated T1/T2 isoforms) were upregulated by LRH1 in stable PC cells
(Fig. 1A). Cyclin E is converted to T1/T2 by calpain1 through post-translational processing.
LRH1-mediated cyclin E T1/T2 overexpression was attributed to upregulation of ERα—
Calpain1 signaling (Fig. 1B).
3.3 LRH1 promotes PC cell proliferation
LRH1 overexpression resulted in a significant increase in PC cell proliferation compared
with the control (Fig. 2). Both AspC-1 and Capan-1 cells expressing LRH1 obtained a
selective growth advantage and presented a higher proliferation rate than the control.
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3.4 Tumorigenicity of LRH1 in vivo
In vitro observations suggest that LRH1 expression is important for PC cell proliferation.
Therefore, we explored its oncogenic role using an in vivo model (Fig. 3). We measured the
resulting tumor growth in the immune deficient mice after injection of parental and LRH1transfected PC cells. Following introduction and expression of LRH1, Capan-1 cells
generated significantly enhanced s.c. tumor growth characterized by a higher tumor weight
compared to vectors (895 ± 135 mg vs. 514 ± 151 mg, p<0.01) (Fig. 3A). Histologically, in
the tissue of s.c. tumor derived from LRH1 expressing cells was characterized by
hyperchromatic, pleomorphic and irregular nuclei with prominent nucleoli and abundance of
large cells with clear cytoplasm reminiscent of “signet ring” cells (Fig. 3B). The tumors
derived from LRH1 expressing cells displayed a higher Ki67 Index (27.9% vs. 18.9%,
p<0.0001) (Fig. 3C) and formed highly vascularized tissue compared with tumor from
control cells as shown by enhanced CD34 staining of endothelial cells depicted by a
representative example in Fig. 3D (n=7).
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3.5 Expression of LRH1, cyclin D1, cyclin E1, and calpain1 in patients with PC
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We hypothesize that downstream target genes are activated and upregulated corresponding
to LRH1 overexpression in PC patients. The expression profiling of LRH1-related genes in
human pathologic specimens was examined. LRH1 was overexpressed in 15/18 (83.3%) of
tumors in PC patients (Fig. 4). Consistent with the in vitro findings of LRH1 overexpression
in PC cell lines, cyclin D1, cyclin E1, and calpain1 were also overexpressed in tumorous
tissues as well compared with adjacent normal pancreas derived from PC patients (Fig. 4).

4. DISCUSSION
We have found that LRH1 overexpression enhanced upregulation of downstream targets and
contributed to cell proliferation, as well as tumor formation and angiogenesis in nude mice.
Based on these observations, LRH1 is proposed to act as a driving factor for PC growth as
detailed by the diagram presented in Fig. 5.
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LRH1 promotes PC cell proliferation by inducing G1 cyclin D1/E1 and thus cell cycle
transition from G1 to S phase.[4] Cyclins promote DNA synthesis by initiating cyclindependent kinase activation, retinoblastoma phosphorylation and E2F transcriptional factors
activation. LRH1 upregulates the expression of downstream targets (cyclin D1/E1) in PC
cells, which is also consistent with the results of previous studies.[4, 5, 11] The cell cycle
regulators cyclin D1/E1 are frequently overexpressed in gastrointestinal tumors [11] and
contribute to oncogenesis in animal models.[16]
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LRH1 upregulates the expression of cyclin E truncated T1/T2 isoforms in PC cells. Cyclin E
is up-regulated in a variety of malignancies such as breast cancer [6] and melanoma.[2] In
tumors, cyclin E deregulation produces five low molecular weight (LMW) isoforms via
post-translational processing by calpain1/2. LMW cyclin E (LMW-E), which is not found in
normal tissue, caused genomic instability, induced resistance to p21/p27-mediated apoptosis
and anti-estrogen therapy, and correlated with decreased survival of patients with breast
cancer.[6] Both primary tumor formation and metastasis were increased in LMW-E
transgenic mice compared to the full-length cyclin E (EL). Moreover, LMW-E selects for
spontaneous inactivation of the ARF-p53 pathway by loss of heterozygosity, blocking its
protective checkpoint function and accelerating progression to malignancy. LMW-E is also
overexpressed in metastatic melanoma and primary invasive melanoma, but not in benign
nevi. Overexpression of cyclin E T1/T2 generated more angiogenic melanoma with
prominent perineural invasion and displayed as a large increase in lung metastases compared
with EL.[2] Using frozen tissue samples from PC patients, we detected overexpression of
LRH1 and cyclin E T2 in tumors compared to the normal pancreas. The results support the
critical involvement of upregulated cyclin E T2 signaling in contributing to tumor growth
and angiogenesis of PC.
Structure-based discovery of LRH1 antagonists has identified ligands that inhibit LRH1
transcriptional activity and diminish expression of the receptor’s target genes.[3] In this
regard, a number of potential LRH1 antagonists are under investigation for analyses of the
receptor’s biological mechanisms.
In summary, our study revealed that overexpressed LRH1 promotes cell proliferation, tumor
formation and angiogenesis. Our observations demonstrate that the LRH1 receptor may play
a role in driving tumor growth of PC (Fig. 5).
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Fig. 1.

LRH1 upregulated downstream target genes in PC. (A) Endogenous expression of LRH1 in
PC cell lines. LRH1 was highly expressed in MIA PaCa-2 and Hs766T, compared with
HPDE (negative control), as well as HepG2 and HEK-293 cells transfected with pcDNA3LRH1 (positive controls). (B) Expression levels of cyclin D1 and cyclin E1 truncated T1/T2
isoforms were significantly upregulated in LRH1 overexpressing stable Capan-1 and
AsPC-1 cells than in controls. Cyclin E1 (FL), full length cyclin E1. (C) The mRNA levels
of cyclin D1/E1 were upregulated in PC cell line.
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Fig. 2.

Growth curves of stable PC cells with LRH1 overexpression. Accelerated cell growth was
observed in LRH1 stable transfected Capan-1 and AsPC-1 cells than in controls (Student t
test, 2-tailed, *p<0.01).
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Fig. 3.

LRH1 promoted PC tumor growth in nude mice. (A) Representative established
subcutaneous (s.c.) tumors by inoculation of 1×107 Capan-1 cells transfected with LRH1 or
vector control. Right shoulder tumors were derived from LRH1-transfected cells, left
shoulder tumors were derived from vector control cells. Tumor weights were analyzed
within 3 weeks after inoculation of Capan-1 cells stably transfected with LRH1 or vectors
(n=7). Compared to vectors, LRH1 expressing stable Capan-1 cells produced much larger
tumors (paired t test, 2-tailed, **p<0.01). Vertical bars, standard error. (B) H&E staining of
two subcutaneous tumors. (C) Proliferation Index as measured by positive Ki67 staining of
tumor nuclei (Student t test, 2-tailed, ***p<0.0001). (D) Examples of enhanced CD34
expression in endothelial indicating increased vascularity in two LRH1 induced tumors.
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Fig. 4.

Representative examples of LRH1 related genes expression in PC. Weak-negative staining
for LRH1 (a1), cyclin D1 (b1), cyclin E1 (c1), and calpain1 (d1) was observed for all
components of normal exocrine pancreas. In human PC tumor cells, elevated levels of LRH1
(a2), cyclin D1 (b2), cyclin E1 (c2), and calpain1 (d2) were detected. The original
magnification (×40) is specified.

NIH-PA Author Manuscript
Cancer Lett. Author manuscript; available in PMC 2015 April 01.

Lin et al.

Page 12

NIH-PA Author Manuscript
NIH-PA Author Manuscript

Fig. 5.

Hypothesized oncogenic role of LRH1 in PC. We suggest that LRH1 promotes PC tumor
growth and angiogenesis by upregulating cyclin D1/E1. In combination with estrogen (E)
and estrogen receptor (ER), LRH1 acts to upregulate caplain1. Calapin1 is known to convert
full-length cyclin E1 into truncated T1/T2 isoforms through post-translational processing [2,
6]. These isoforms may exhibit enhanced oncogenic and angiogenic properties [2, 6].
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